Bibliografía del artículo
1. Borrego L. Etanercept en el embarazo y lactancia. Actas Dermosifiliogr 101(Supl. 1):97-101, 2010.
2. Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 334:1218-20, 2007.
3. Joven BE, García-González AJ, Ruiz T, Moreno E, Cebrián L, Valero M. Pregnancy in women receiving anti-TNF therapy. Experience in Spain. Arthritis Rheum 9:S349, 2005.
4. Otermin I, Elizondo G, Zabaleta J, Amigot A. Etanercept y embarazo. An Sist Sanit Navar 30:491-3, 2007.
5. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, et al. From the medical board of the national psoriasis foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58(1):94-105, 2008.
6. Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, et al. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. Actas Dermosifiliogr 100(05):386-413, 2009.
7. Moreno Ramírez D, Domínguez Castellano A. Vacunación del paciente con psoriasis en tratamiento biológico. Piel 26:25-30, 2011.
8. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18:257-64, 2004.
9. Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 75:1093-8, 2000.
10. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 34:1353-5, 2007.
11. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 144:453-6, 2008.
12. Barco D, Puig L, Alomar A. Tratamiento de la psoriasis moderada-grave con etanercept en pacientes con infección crónica por el virus de la inmunodeficiencia humana. Actas Dermosifiliogr 101(Supl. 1):77-81, 2010.
13. Bordas X, Martín Sala S. Etanercept e infección crónica por los virus de la hepatitis C y B. Actas Dermosifiliogr 101(Supl. 1):82-87, 2010.
14. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Derm 54:361-2, 2006.
15. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54:1102-4, 2006.
16. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Derm 51:580-4, 2004.
17. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51:800-4, 2004.
18. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29:1021-9, 2010.
19. Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF alpha blockade. Rheumatology (Oxford) 46:1381-2, 2007.
20. García Rabasco A, Sánchez Carazo JL, Esteve A. Etanercept y neoplasias. Actas Dermosifiliogr 101(Supl. 1):88-96, 2010.
21. Gelfand JM, Berlín J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis. Arch Dermatol 139:1425-9, 2003.
22. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Muñoz O, Boussiotis V, et al. Targeting the follicular lymphoma microenviroment through blockade of TNF alfa with etanercept. Leuk Lymphoma 49:902-9, 2008.
23. Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 42:900-1, 2003.
24. Meyboom RHB, Star K, Bate J. Edwards IR. TNF-a inhibitors and leukaemia: International Pharmacovigilance Reports. Drug Safety 31:445-7, 2008.
25. Klareskog L, Moreland L, Cohen S, et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy. Arthritis Rheum 44:S77, 2001.
26. Fulchiero GJ, Salvaggio H, Drabick JJ, Staveley-O´Carroll K, Billingsley EM, Marks JG, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56:S65-7, 2007.
27. Rodríguez E, Hernández G, Díaz O, Tello O. Casos de tuberculosis declarados a la Red Nacional de Vigilancia Epidemiológica. España, 2007. Boletín Epidemiológico Semanal 16:229-40, 2008.
28. González-Sixto B, Rodríguez-Prieto MA. Etanercept e infección latente tuberculosa. Actas Dermosifiliogr 101(Supl. 1):62-69, 2010.
29. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious due to tumor necrosis factor blockage: correction. Clin Infect Dis 39:1254-6, 2004.
30. Puig L, Bordas X, Carrascosa JM, Daudén E, Ferrándiz C, Hernanz JM, et al. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr 100:277-86, 2009.
31. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before initiation of anti-TNF-a therapy. Swiss Med Wkly 137:621-2, 2007.
32. Gupta A, Street AC, Macrae A. Tumor necrosis factor a inhibitors: screening for tuberculosis infection in inflammatory bowel disease. MJA 188:168-70, 2008.
33. Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. Can Commun Dis Rep 34:1-13, 2008.